Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iGlarLixi vs Standard of Care in Uncontrolled Type 2 Diabetes in China
NCT07307235Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by Zhongshan Hospital, Fudan University. Started Dec 2025; status: recruiting.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07307235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07307235.